Active Biotech develops innovative pharmaceuticals that modulate the body's own immune system.We focus on widespread diseases for which a tremendous need is felt for new and more effective treatments.

2010-02-08	TEVA ACQUIRES MARKETING RIGHTS FOR ORAL LAQUINIMOD IN THE NORDIC AND BALTIC REGIONS
2009-12-14	Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients
2009-11-05	Active Biotech's election committee appointed
2009-11-05	Active Biotech AB Interim Report, January - September 2009
2009-10-05	RhuDex Clinical Development to Continue Following Feedback from Regulatory Authorities
2009-09-25	Active Biotech's Prostate Cancer Project TASQ Featured in British Journal of Cancer

Active Biotech AB, Scheelevägen 22, P.O. Box 724, SE-220 07 Lund, Sweden, Telephone +46 46 19 20 00